Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Colorcon
AstraZeneca
Boehringer Ingelheim
Medtronic

Last Updated: October 2, 2022

Investigational Drug Information for CTA018


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug CTA018?

CTA018 is an investigational drug.

There have been 3 clinical trials for CTA018. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2006.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Neoplasm Metastasis, and Kidney Failure, Chronic. The leading clinical trial sponsors are OPKO Health, Inc., OPKO IP Holdings II, Inc., and [disabled in preview].

Recent Clinical Trials for CTA018
TitleSponsorPhase
Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)OPKO Health, Inc.Phase 2
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney DiseaseOPKO IP Holdings II, Inc.Phase 2
Safety and Efficacy of Topically Applied CTA018 in Plaque PsoriasisOPKO Health, Inc.Phase 2

See all CTA018 clinical trials

Clinical Trial Summary for CTA018

Top disease conditions for CTA018
Top clinical trial sponsors for CTA018

See all CTA018 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Colorcon
AstraZeneca
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.